Kymera's KT-579 shows strong preclinical results for IBD, with Phase 1 trial data due in late 2026

Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader, showing it effectively modulates multiple inflammatory pathways in inflammatory bowel disease (IBD) models. KT-579 demonstrated comparable or superior activity to existing therapies by reducing key inflammatory cytokines and improving disease markers. The drug is currently in a Phase 1 trial with healthy volunteers, focusing on safety and IRF5 degradation, with results expected in the second half of 2026. This novel oral treatment could offer a new option for patients with complex autoimmune diseases like IBD.